<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811664</url>
  </required_header>
  <id_info>
    <org_study_id>CoVPN 3006</org_study_id>
    <nct_id>NCT04811664</nct_id>
  </id_info>
  <brief_title>A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine</brief_title>
  <acronym>CoVPN 3006</acronym>
  <official_title>A Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess SARS CoV-2 infection, viral shedding, and subsequent&#xD;
      potential transmission in individuals immunized with the Moderna COVID-19 vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the efficacy of the Moderna COVID-19 vaccine against SARS-CoV-2&#xD;
      infection, as well as its effect on peak nasal viral load as a measure of infection and a&#xD;
      proxy of infectiousness, in adults aged 18-29.&#xD;
&#xD;
      In the Main study, up to 12,000 participants will be randomized 1:1 to Immediate Vaccination&#xD;
      Group 1 (at Months 0 and 1) or Standard of Care Group 2, with vaccination given at Months 4&#xD;
      and 5 if not received off-study previously. Up to an additional 6,000 participants will be&#xD;
      enrolled into the Vaccine Declined Group 3 and will also be offered vaccine at Months 4 and&#xD;
      5.&#xD;
&#xD;
      Additional study visits for Group 1 will occur at Months 2 and 4; for Groups 2 and 3, at&#xD;
      Months 0 and 2. Study visits may include medical history, vaccine injections, blood&#xD;
      collection, nasal swab, SARS-CoV-2 screening, COVID-19 symptom check, and questionnaires.&#xD;
&#xD;
      In addition to the main study participants, the study will also evaluate infectiousness&#xD;
      following close contacts with main study participants. Study procedures for close contacts&#xD;
      include questionnaires and blood samples; for those who become SARS-CoV-2 infected, study&#xD;
      procedures will also include nasal swabs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">December 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Moderna COVID-19 Vaccine against SARS-CoV-2 infection</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>SARS-CoV-2 infection diagnosed by PCR among participants who were SARS-CoV-2 seronegative at enrollment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Moderna COVID-19 Vaccine on peak nasal viral load</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>As a measure of infection and a proxy of infectiousness, peak viral load in nasal samples from participants diagnosed with SARS-CoV-2 infection among participants who were SARS-CoV-2 seronegative at enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of Moderna COVID-19 Vaccine on secondary transmission of SARS-CoV-2 infection</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>Evaluated by the number of secondary transmission events in close-contact cohorts from main study participants who were SARS-CoV-2 seronegative at enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Moderna COVID-19 Vaccine to prevent serologically confirmed SARS-CoV-2 infection</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>Evaluated by SARS-CoV-2 antibodies to the nucleocapsid protein post Month 1 visit among participants who were SARS-CoV-2 seronegative at enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Moderna COVID-19 Vaccine against COVID-19 disease confirmed by PCR test and symptoms</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>Evaluated by SARS-CoV-2 infection confirmed by PCR among participants who were SARS-CoV-2 seronegative at enrollment; reporting at least 2 of the following systemic symptoms: Fever (≥ 38ºC), chills, myalgia, headache, sore throat; or reporting at least one of the following signs/symptoms: cough, shortness of breath or difficulty breathing, new olfactory or taste disorder, clinical or radiographical evidence of pneumonia, thromboembolic event, myocardial infarction, myocarditis, chilblains, or multi-inflammatory syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Moderna COVID-19 Vaccine on magnitude of viral load over time</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>Summary measures of the viral load curve, all evaluated among participants diagnosed with SARS-CoV-2 infection who were SARS-CoV-2 seronegative at enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Moderna vaccine regardless of baseline serostatus (SARS-CoV-2 infection by PCR)</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>Evaluated by SARS-CoV-2 infection diagnosed by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Moderna vaccine on viral load regardless of baseline serostatus (Viral load)</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>Evaluated by peak viral load in nasal samples from diagnosed participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Moderna vaccine on secondary status regardless of baseline serostatus (Secondary transmission events)</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>Evaluated by number of secondary transmission events in close-contact cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Moderna COVID-19 vaccine</measure>
    <time_frame>Measured through Month 2</time_frame>
    <description>Magnitude and response rate of immune responses to vaccination as measured by binding antibody and neutralization assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune responses as correlates of risk of SARS-CoV-2 acquisition, viral load, secondary infection, and COVID-19 disease</measure>
    <time_frame>Measured through Month 2</time_frame>
    <description>Magnitude and response rate of immune responses to vaccination as measured by binding antibody and neutralization assays</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Moderna COVID-19 vaccine against asymptomatic SARS-CoV-2 infection</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>SARS-CoV-2 infection by PCR or periodic serology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Moderna COVID-19 Vaccine against SARS-CoV-2 infection and COVID-19 disease</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>SARS-CoV-2 infection diagnosed by PCR among participants who were SARS-CoV-2 seronegative at enrollment and who received all planned immunizations at designated immunization visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Moderna COVID-19 Vaccine on viral load</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>Measure of peak viral load among participants who were SARS-CoV-2 seronegative at enrollment and who received all planned immunizations at designated immunization visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Moderna COVID-19 Vaccine on secondary transmission</measure>
    <time_frame>Measured through Month 4 study visit</time_frame>
    <description>Measure of secondary transmission events among participants who were SARS-CoV-2 seronegative at enrollment and who received all planned immunizations at designated immunization visits</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">37500</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Immediate Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml IM into the deltoid muscle on Day 1 and Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Moderna COVID-19 Vaccine in 100 mcg dose given as 0.5 ml IM into the deltoid muscle on Day 113 and Day 141.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine Declined</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants who prefer not to be vaccinated, If requested, participant will be offered vaccine if they have not received vaccine outside of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Moderna COVID-19 Vaccine</intervention_name>
    <description>A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.</description>
    <arm_group_label>Delayed Vaccination</arm_group_label>
    <arm_group_label>Immediate Vaccination</arm_group_label>
    <other_name>mRNA-1273</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Immediate Vaccination and Standard of Care Groups:&#xD;
&#xD;
          -  Willingness to be followed for the planned duration of the study.&#xD;
&#xD;
          -  Agrees to allow study staff to access school SARS-CoV-2 testing data and outcomes, if&#xD;
             applicable.&#xD;
&#xD;
          -  Ability and willingness to provide informed consent.&#xD;
&#xD;
          -  Assessment of understanding: volunteer demonstrates understanding of this study;&#xD;
             completes a questionnaire with demonstration of understanding of all questionnaire&#xD;
             items answered incorrectly.&#xD;
&#xD;
          -  Willing to be randomized to either immediate vaccination or standard of care group and&#xD;
             comply with planned study procedures&#xD;
&#xD;
          -  Agrees not to enroll in another study of an investigational research agent until the&#xD;
             end of the study.&#xD;
&#xD;
          -  Access to device and internet for completion of study procedures.&#xD;
&#xD;
        Exclusion Criteria for Immediate Vaccination and Standard of Care Groups:&#xD;
&#xD;
          -  Acutely ill 72 hours prior to or at screening. Volunteers meeting this criterion may&#xD;
             be rescheduled within the relevant window periods. Participants with minor illnesses&#xD;
             can be enrolled at the discretion of the investigator.&#xD;
&#xD;
          -  Blood products, systemic immunoglobulins, or monoclonal antibodies (including against&#xD;
             SARS-CoV-2) received within 90 days before first vaccination.&#xD;
&#xD;
          -  Investigational research agents received within 30 days before first vaccination.&#xD;
&#xD;
          -  Self-reported known history of SARS-CoV-2 infection.&#xD;
&#xD;
          -  Prefers to receive COVID-19 vaccination immediately, (These volunteers to be referred&#xD;
             to community resources for vaccination).&#xD;
&#xD;
          -  Prior administration of a coronavirus (SARS-CoV-2, SARS-CoV, MERS-CoV) vaccine or&#xD;
             current/planned simultaneous participation in another interventional study to prevent&#xD;
             or treat COVID-19.&#xD;
&#xD;
          -  Immunosuppressive medications received within 168 days before first vaccination (not&#xD;
             exclusionary: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical&#xD;
             corticosteroids for mild, uncomplicated dermatologic condition; or [4] a single course&#xD;
             of oral/parenteral prednisone or equivalent at doses &lt; 60 mg/day and length of therapy&#xD;
             &lt; 11 days with completion at least 30 days prior to enrollment).&#xD;
&#xD;
          -  Clinically significant medical condition, physical examination findings, or past&#xD;
             medical history with clinically significant implications for current health. A&#xD;
             clinically significant condition or process includes but is not limited to a process&#xD;
             that would affect the immune response (well-controlled human immunodeficiency virus&#xD;
             infection is allowed), or any condition specifically listed among the exclusion&#xD;
             criteria below.&#xD;
&#xD;
          -  Any medical, psychiatric, occupational, or other condition that, in the judgment of&#xD;
             the investigator, would interfere with, or serve as a contraindication to, protocol&#xD;
             adherence, assessment of safety or reactogenicity, or a volunteer's ability to give&#xD;
             informed consent.&#xD;
&#xD;
          -  Bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder requiring&#xD;
             special precautions).&#xD;
&#xD;
          -  Asplenia: any condition resulting in the absence of a functional spleen.&#xD;
&#xD;
          -  History of angioedema or anaphylaxis, including to vaccines or vaccine components (not&#xD;
             exclusionary: angioedema or anaphylaxis with known trigger and no episodes within five&#xD;
             years.).&#xD;
&#xD;
          -  History of generalized urticaria within past five years.&#xD;
&#xD;
        Inclusion Criteria for Vaccine Declined Group:&#xD;
&#xD;
          -  Ability and willingness to provide informed consent.&#xD;
&#xD;
          -  Prefers not to receive COVID-19 vaccine.&#xD;
&#xD;
          -  Willingness to be followed for the planned duration of the study.&#xD;
&#xD;
          -  Assessment of understanding: volunteer demonstrates understanding of this study;&#xD;
             completes a questionnaire with demonstration of understanding of all questionnaire&#xD;
             items answered incorrectly.&#xD;
&#xD;
          -  Access to device and internet for completion of study procedures.&#xD;
&#xD;
        Exclusion criteria for Vaccine Declined Group:&#xD;
&#xD;
          -  Prior administration of a coronavirus (SARS-CoV-2, SARS-CoV, MERS-CoV) vaccine or&#xD;
             current/planned simultaneous participation in another interventional study to prevent&#xD;
             or treat COVID-19 (participation in studies of other investigational research agents&#xD;
             allowed).&#xD;
&#xD;
          -  Any medical, psychiatric, occupational, or other condition that, in the judgment of&#xD;
             the investigator, would interfere with, or serve as a contraindication to, protocol&#xD;
             adherence, or a volunteer's ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Stephenson</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Audrey Pettifor</last_name>
    <role>Study Chair</role>
    <affiliation>Gillings School of Global Public Health, University of North Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jasmine Marcelin</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Goepfert</last_name>
      <phone>205-996-4405</phone>
      <email>paulg@uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Headlands Research Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Weber</last_name>
      <phone>480-927-3800</phone>
      <email>Jeffrey.weber@headlandsresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMR Phoenix</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corey Anderson</last_name>
      <phone>602-910-3343</phone>
      <email>corey.anderson@amrllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Connick, MD</last_name>
      <phone>520-626-6887</phone>
      <email>connicke@email.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charles Drew University</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Vadgama</last_name>
      <phone>323-563-4853</phone>
      <email>jayvadgama@cdrewu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Cohen</last_name>
      <phone>916-734-6943</phone>
      <email>stcohen@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Little</last_name>
      <phone>619-543-8080</phone>
      <email>slittle@health.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado- Boulder</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher DeSouza, PhD</last_name>
      <phone>303-492-2988</phone>
      <email>christopher.desouza@Colorado.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JEM Headlands LLC</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Bush</last_name>
      <phone>561-968-2933</phone>
      <email>lbush@jemri.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kartik Cherabuddi</last_name>
      <phone>352-294-5481</phone>
      <email>Kartikeya.Cherabuddi@medicine.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UF CARES</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mobeen Rathore</last_name>
      <phone>904-244-5331</phone>
      <email>mobeen.rathore@jax.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center CRS</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charlotte-Page Rolle</last_name>
      <phone>407-647-3960</phone>
      <phone_ext>2125</phone_ext>
      <email>CRolle@oicorlando.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Headlands Research Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mallitz</last_name>
      <phone>941-529-8978</phone>
      <email>michelle.mallitz@headlandsresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kami Kim</last_name>
      <phone>813-974-5891</phone>
      <email>kamikim@usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Morehouse University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilly Immergluck</last_name>
      <phone>404-756-1326</phone>
      <email>limmergluck@msm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Hope Clinic of the Emory Vaccine Center CRS</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sri Edupuganti</last_name>
      <phone>404-712-1370</phone>
      <email>sedupug@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Champaign-Urbana Public Health District</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Shisler</last_name>
      <phone>217-265-6450</phone>
      <email>jshisler@illinois.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Sha</last_name>
      <phone>312-942-5865</phone>
      <email>Beverly_Sha@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Krueger</last_name>
      <phone>312-694-0414</phone>
      <email>karen.krueger@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47405-7000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Rosenberg, PhD</last_name>
      <phone>812-856-2509</phone>
      <email>rosenmol@indiana.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ, of Kansas School of Medicine CRS</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffany Schwasinger-Schmidt</last_name>
      <phone>316-293-1833</phone>
      <email>tschwasinger-schmidt@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Greenberg</last_name>
      <phone>859-323-6327</phone>
      <email>rngree01@uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc. - Lake Charles</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Whatley</last_name>
      <phone>337-244-0590</phone>
      <email>jwhatley@centexstudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland College Park</name>
      <address>
        <city>College Park</city>
        <state>Maryland</state>
        <zip>20742-2611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Sehgal</last_name>
      <phone>301-405-2469</phone>
      <email>sehgal@umd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fenway Health (FH) CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-4302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Mayer</last_name>
      <phone>617-927-6021</phone>
      <email>Kmayer@fenwayhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wayne State - Harper Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Kilgore</last_name>
      <phone>313-745-7105</phone>
      <email>paul.kilgore@wayne.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Kline</last_name>
      <phone>612-624-3046</phone>
      <email>kline003@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia - Missouri VTEU</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hasan Naqvi</last_name>
      <phone>573-884-9075</phone>
      <email>naqvis@health.missouri.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Presti</last_name>
      <phone>314-747-1098</phone>
      <email>prestir@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rusty McCulloh</last_name>
      <phone>402-995-6088</phone>
      <email>russell.mcculloh@unmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AMR Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Jacobs</last_name>
      <phone>702-597-9825</phone>
      <email>Michael.jacobs@amrllc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregory Mertz</last_name>
      <phone>505-272-6042</phone>
      <email>GMertz@salud.unm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bronx Prevention Research Center CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Justman</last_name>
      <phone>347-590-7280</phone>
      <email>jj2158@columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Long Island Vaccine Center</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mulligan</last_name>
      <phone>516-663-9709</phone>
      <email>mark.mulligan@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Bellevue Vaccine Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mulligan</last_name>
      <phone>347-829-7309</phone>
      <email>mark.mulligan@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harlem Prevention Center CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Mannheimer</last_name>
      <phone>212-939-2848</phone>
      <email>sbm20@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Blood Center CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Van Tieu</last_name>
      <phone>212-388-0008</phone>
      <email>htieu@nybloodcenter.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Nachman</last_name>
      <phone>631-444-7692</phone>
      <email>Sharon.Nachman@stonybrookmedicine.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Becker Dreps</last_name>
      <phone>984-974-4662</phone>
      <email>sbd@email.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Sanders</last_name>
      <phone>336-716-0908</phone>
      <email>jwsander@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn Prevention CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Miriam Hopsital CRS</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Tashima</last_name>
      <phone>401-793-4771</phone>
      <email>KTashima@Lifespan.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clemson University</name>
      <address>
        <city>Clemson</city>
        <state>South Carolina</state>
        <zip>29634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Kalbaugh, PhD</last_name>
      <phone>864-656-6694</phone>
      <email>Coreyk@clemson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Vaccine CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spyros Kalams</last_name>
      <phone>615-343-6906</phone>
      <email>s.kalams@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Tech</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tarek Naguib</last_name>
      <phone>806-414-9736</phone>
      <email>Tarek.Naguib@ttuhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc. - Brownsville</name>
      <address>
        <city>Brownsville</city>
        <state>Texas</state>
        <zip>78526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Solis</last_name>
      <phone>832-902-2237</phone>
      <email>jsolis@centexstudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas A&amp;M University</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77843</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Fischer, PhD</last_name>
      <phone>979-436-9393</phone>
      <email>rfischer@tamu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc. - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Pouzar</last_name>
      <phone>281-282-0808</phone>
      <email>joepouzar@centexstudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc. - Westfield</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ail Bajwa</last_name>
      <phone>346-235-3488</phone>
      <email>abajwa@centexstudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas A&amp;M - Kingsville</name>
      <address>
        <city>Kingsville</city>
        <state>Texas</state>
        <zip>77843</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Udeani</last_name>
      <phone>361-221-0701</phone>
      <email>udeani@tamu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc. - McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric R Houpt, MD</last_name>
      <phone>434-243-9326</phone>
      <email>erh6k@virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Chu</last_name>
      <phone>206-685-5386</phone>
      <email>helenchu@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

